Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/003332PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2022/010552 Applicant BIOAPPLICATIONS INC. Inventor SOHN, Eun-Ju
The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
2.WO/2023/001781PROCESS FOR THE PREPARATION OF N-HYDROXYPYRIDONE COMPOUNDS
WO 26.01.2023
Int.Class C07D 213/89
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
89with hetero atoms directly attached to the ring nitrogen atom
Appl.No PCT/EP2022/070105 Applicant CLARIANT INTERNATIONAL LTD Inventor FISCH, Lothar
The invention relates to a process for the preparation of N- hydroxypyridone compounds (I) from pyrone compounds. The N- hydroxypyridone compounds (I) can be used as anti-dandruff agents or as preservatives.
3.WO/2023/003002ANNULATED PYRIDAZINE COMPOUND
WO 26.01.2023
Int.Class C07D 237/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
30Phthalazines
32with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Appl.No PCT/JP2022/028138 Applicant ASTELLAS PHARMA INC. Inventor INAGAKI, Yusuke
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the present invention conducted extensive studies to find a compound that has an inhibiting action on NLRP3 inflammasome activation, and found that an annulated pyridazine compound has an inhibiting action on NLRP3 inflammasome activation, leading to the achievement of the present invention. The annulated pyridazine compound according to the present invention is expected to serve as a drug for preventing and/or treating inflammatory diseases and/or a neurodegenerative diseases.
4.WO/2023/001982MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
WO 26.01.2023
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2022/070541 Applicant UNIVERSITÄT BASEL Inventor FLOHR, Alexander
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adducts occurring in eukaryotic cells under certain conditions. The invention further relates to pharmaceutical preparations and methods for use of such ligands in treatment and research. The invention further relates to pharmaceutical preparations provided with the aim of modulating presentation of MR1 ligands in clinical situations where such modulated presentation of MR1 ligands is of clinical benefit.
5.WO/2023/000962CORE-SHELL QUANTUM DOT, QUANTUM DOT LIGHT-EMITTING DEVICE, DISPLAY APPARATUS AND MANUFACTURING METHOD
WO 26.01.2023
Int.Class C09K 11/88
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR APPLICATIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
11Luminescent, e.g. electroluminescent, chemiluminescent, materials
08containing inorganic luminescent materials
88containing selenium, tellurium or unspecified chalcogen elements
Appl.No PCT/CN2022/103427 Applicant BOE TECHNOLOGY GROUP CO., LTD. Inventor MEI, Wenhai
A core-shell quantum dot, a quantum dot light-emitting device, a display apparatus and a manufacturing method. The core-shell quantum dot comprises: a core part; a shell layer, which is located on at least part of a surface of the core part, and comprises metal ions; and a chelating ligand, which is connected to the metal ions, the chelating ligand and the metal ions forming a closed ring structure, which is connected to the shell layer.
6.WO/2023/001247PYRIDAZINONE COMPOUND
WO 26.01.2023
Int.Class C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Appl.No PCT/CN2022/107127 Applicant MEDSHINE DISCOVERY INC. Inventor FU, Xiangyu
A series of pyridazinone compounds and pharmaceutically acceptable salts thereof, and an application thereof in the preparation of a drug for treating a related disease. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.
7.WO/2023/004367ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/US2022/073968 Applicant THE BROAD INSTITUTE, INC. Inventor DEVERMAN, Benjamin
Highly selective targeting moieties and compositions comprising the targeting moieties are described herein to efficiently transduce endothelial cell of the central nervous system vasculature. Embodiments include use and delivery of the targeting moieties and compositions to selectively direct delivery of cargo.
8.WO/2023/004337HEAT EXCHANGE CONFIGURATIONS FOR OLIGOMERIZATION OF OLEFINS
WO 26.01.2023
Int.Class C07C 2/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms
02by addition between unsaturated hydrocarbons
04by oligomerisation of well-defined unsaturated hydrocarbons without ring formation
06of alkenes, i.e. acyclic hydrocarbons having only one carbon-to-carbon double bond
Appl.No PCT/US2022/073917 Applicant CHEVRON PHILLIPS CHEMICAL COMPANY LP Inventor KREISCHER, Bruce E.
Disclosed herein are processes and reaction systems for controlling a temperature of an oligomerization reaction zone using a heat exchange system.
9.WO/2023/004307T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION AND TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION
WO 26.01.2023
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/US2022/073881 Applicant EPIVAX, INC. Inventor DE GROOT, Anne
The present disclosure generally relates to novel epitope-based compositions, including vaccines, against respiratory syncytial virus (RSV) infection and diseases caused by RSV. The disclosure relates to immunogenic polypeptides and the uses thereof, particularly in vaccine compositions. The disclosure also relates to nucleic acids, vectors, and cells which express the polypeptides and the uses thereof. The polypeptides more specifically comprise an agretope predicted to be a ligand of HLA class I and/or HLA class II MHC molecules, as well as an epitope that is predicted to be recognized by T-cells in the context of MHC class I and/or class II molecules. The compositions are particularly suited to produce vaccines, particularly for vaccinating against RSV infection and related diseases caused by RSV.
10.WO/2023/004382SUBSTITUTED HETERO-BICYCLOCOMPOUNDS AS SUBTYPE SELECTIVE NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
WO 26.01.2023
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/US2022/073998 Applicant THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS Inventor RILEY, Andrew
In one aspect, the disclosure relates to a scaffold for a class of small molecules that selectively inhibit the α3β4 nicotinic acetylcholine receptor (nAChR) subtype, as well as molecules constructed using the scaffold and syntheses thereof. In some aspects, the scaffold can be used as a basis for synthesizing additional molecules capable of selectively inhibiting other nAChR subtypes. In a further aspect, the disclosed small molecules can be used as molecular probes to investigate the function of different nAChR subtypes and as potential treatments for addiction and other diseases.